PrBa/sub 2/Cu/sub 3/O/sub 7/
Optimization of Process Parameters of Methane Decomposition in a Fluidized Bed Reactor UsingNi-Cu/Al<sub>2</sub>O<sub>3</sub> Catalysts - Volume 3 Number 1 (Feb. 2012) - IJCEA
5
Comparative Study on Convection and Wall Characteristics of Al<sub>2</sub>O<sub>3</sub> water Nanofluid Flow inside a Miniature Tube
13
Toxicity evaluation of Gd<sub>2</sub>O<sub>3</sub>@SiO<sub>2</sub> nanoparticles prepared by laser ablation in liquid as MRI contrast agents in vivo
11
Reactivity of Au/La<sub>1 x</sub>Sr<sub>x</sub>Cr<sub>1 y</sub>Ni<sub>y</sub>O<sub>3 δ</sub> toward Oxidative Coupling of Methane for C<sub>2</sub> and C<sub>3</sub> Hydrocarbons Production
12
In vitro and in vivo targeting imaging of pancreatic cancer using a Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> nanoprobe modified with anti-mesothelin antibody
13
An investigation into the efficacy of intra-articular ozone (O<sub>2</sub>–O<sub>3</sub>) injection in patients with knee osteoarthritis: a systematic review and meta-analysis
14
The effect of magnetic nanoparticles of Fe<sub>3</sub>O<sub>4</sub> on immune function in normal ICR mice
7
<p>Local ozone (O<sub>2</sub>–O<sub>3</sub>) versus corticosteroid injection efficacy in plantar fasciitis treatment: a double-blinded RCT</p>
9
Polyetherimide-grafted Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging
13
Pharmacokinetic parameters and tissue distribution of magnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles in mice
6
The Combination of Calcium Oxide and Cu/ZrO<sub>2</sub> Catalyst and their Selective Products for CO<sub>2</sub> Hydrogenation
10
Preparation of Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticles coated with gallic acid for drug delivery
12
Biocompatibility of magnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles and their cytotoxic effect on MCF-7 cells
10
The effects of magnetite (Fe<sub>3</sub>O<sub>4</sub>) nanoparticles on electroporation-induced inward currents in pituitary tumor (GH<sub>3</sub>) cells and in RAW 264.7 macrophages
10
In vitro toxicity of Fe<sub>m</sub>O<sub>n</sub>, Fe<sub>m</sub>O<sub>n</sub>-SiO<sub>2</sub> composite, and SiO<sub>2</sub>-Fe<sub>m</sub>O<sub>n</sub> core-shell magnetic nanoparticles
11
R<sub>2(GFR)</sub>CHADS<sub>2</sub> and R<sub>2(GFR)</sub>CHA<sub>2</sub>DS<sub>2</sub>VASc schemes improved the performance of CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc scores in death risk stratification of Chinese older patients with atrial fibrillation
6
Biocompatibility of Fe<sub>3</sub>O<sub>4</sub>/DNR magnetic nanoparticles in the treatment of hematologic malignancies
6
Biocompatibility of Fe<sub>3</sub>O<sub>4</sub>@Au composite magnetic nanoparticles in vitro and in vivo
15
Fe<sub>3</sub>O<sub>4</sub>-based PLGA nanoparticles as MR contrast agents for the detection of thrombosis
14
Effect of interaction of magnetic nanoparticles of Fe<sub>3</sub>O<sub>4</sub> and artesunate on apoptosis of K562 cells
8